Subjective Quality of Life Assessment in Hemodialysis Patients at Different Levels of Hemoglobin following Use of Recombinant Human Erythropoietin

Publisher Website
Google Scholar
Abstract
The quality of life of 12 hemodialysis (HD) patients was assessed in a prospective, blinded, cross-over fashion before treatment with recombinant human erythropoietin (r-HuEPO) and at two different levels of hemoglobin (Hb, 9 and 12 g/dl) by means of an interviewer-based questionnaire, the sickness impact profile (SIP). Patients were matched into two groups with no significant difference for age, weight, Hb (6.3 ± 0.5, x ± SEM, group A, vs. 6.4 ± 0.9 group B), length of hemodialysis or number of years of prior transplantation. SIP was assessed prior to treatment, after reaching the first target Hb (Hb 9 g/dl group A, 12 g/dl group B), after 4 months at that target Hb and after 4 months at the alternative target Hb for each group. For all patients, there was a highly significant improvement in quality of life as assessed by lower SIP scores between the initial and second assessments. This was evident for the physical(8.9 ± 1.4 vs. 2.8 ± 1.0; p < 0.001) and psychosocial (14.9 ± 3.9vs. 4.4 ± l.l;p < 0.01) dimensions. Total scores (16.3 ± 2.4 vs. 5.7 ± 0.9; p < 0.001) showed similar changes, reflecting significant improvement in 10 of 12 possible categories between the first two assessments (p < 0.05 to p < 0.001). Improved scores were maintained but did not change appreciably after the 2nd assessment. There was no significant difference in any score (category, dimensional or total) obtained after 4 months at Hb 9 g/dl compared to those after the same period at Hb 12 g/dl. There was also no significant difference in scores between the two groups at any assessment. Results support an enhanced quality of life from r-HuEPO in HD patients which might not improve beyond a certain level of hemoglobin, as most benefits were evident at a Hb of 9 g/dl.

This publication has 0 references indexed in Scilit: